Heart pumps associated with complications in some patients after heart stent procedure

November 18, 2019

In critically ill patients who require a heart pump to support blood circulation as part of stent procedures, specific heart pumps have been associated with serious complications, according to a new study led by cardiologists at Washington University School of Medicine in St. Louis.

Though the observational study does not prove that the heart pumps -- ventricular assist devices -- are the cause of complications, it suggests that with current practice patterns, there is an association between the use of the pumps and an increased risk of bleeding, kidney problems, stroke and death in patients undergoing stent procedures. The study authors are calling for more research evaluating the heart pumps marketed under the brand name Impella.

Results from the study were presented Nov. 17 at the American Heart Association's Scientific Sessions 2019 in Philadelphia and published simultaneously in the journal Circulation.

After statistically adjusting for certain variables, the researchers found an increased risk of death, bleeding, acute kidney injury and stroke among patients while they were still hospitalized after receiving Impella pumps versus balloon pumps. In particular, the Impella pump was associated with a 24% higher risk of death than seen with balloon pumps and a 34% increased risk of stroke compared with the balloon pump. Both of these differences are statistically significant. In no category was the Impella pump associated with improved outcomes.

"These results deserve a closer look to try to better understand the link between the device and its complications," said lead author Amit P. Amin, MD, a Washington University cardiologist and associate professor of medicine, who is presenting the data. "They suggest that perhaps a more measured approach -- one that balances risks and benefits -- is needed in this critically ill population. These data are observational, so they can't prove causation. But they underscore the need for large, randomized clinical trials and prospective registries to better understand and guide the use of cardiac support devices."

The researchers analyzed data from the Premier Healthcare Database that included information from 48,000 patients treated at 432 U.S. hospitals. Each patient in the study underwent a heart stent procedure, which involves opening a blocked artery in the heart to improve blood flow. Some patients undergoing the stent procedure are seriously ill, often having other medical conditions including heart failure, low blood pressure, complex blockages and other cardiac problems that might lead doctors to decide to add a mechanical assist device during the procedure to help the heart pump a greater volume of blood. Of the patients in this study, just under 10% (4,782 patients) received an Impella heart pump. The remaining 90% (43,524 patients) received an intra-aortic balloon pump.

Most patients undergoing stent procedures don't need a ventricular assist device. This study is focused on the small segment (roughly 3% to 5%) of patients undergoing stent procedures for more advanced heart problems -- such as complex blockages or heart failure or cardiogenic shock, in which the heart loses its capacity to pump sufficient blood -- and need a ventricular assist device. Most patients receive an intra-aortic balloon pump, which rhythmically inflates and deflates in coordination with the heart's natural rhythm, to help push blood through the vessels. These pumps have been in use since the 1960s. But since 2008, a steadily increasing proportion of patients receive the more recently approved Impella pumps, which have small rotors that create a continuous flow of blood.

The data came from patients treated from 2004 to 2016. The Impella pump was introduced into clinical practice in 2008, allowing for comparisons from the time periods before and after this type of pump came into use. Impella use increased steadily from about 1% of patients receiving a pump in 2008 to almost 32% of all patients in 2016 undergoing stent procedures with support devices.

The researchers also found large variations in how often hospitals used Impella pumps. The hospitals that used Impella pumps more frequently had higher adverse outcomes, as well as higher costs associated with caring for these patients, despite controlling for clinical factors. The researchers analyzed the possibility that sicker patients were more likely to receive the Impella pump, perhaps explaining at least part of that association. Instead, they found a trend showing lower Impella use among more critically ill patients.

The authors caution that there are limitations to this observational study, such as physician preference for use of Impella or balloon pumps, or inability to account for factors that were not measured in the observational study. But since the majority of the data suggest no improvement in outcomes linked to the use of the Impella pump as well as serious complications, Amin and his colleagues call for more definitive research to better understand the appropriate role for circulatory support devices in clinical practice.

"These mechanical support devices are innovative and can efficiently pump blood to the body, but in this study, we found no association with improved outcomes with the Impella pumps," Amin said. "This warrants more study so we can understand which patients are likely to benefit from these cardiac assist devices and which are more likely to develop problems."
Dr. Amin has been supported by a comparative effectiveness research KM1 career development award from the Clinical and Translational Science Award (CTSA) program of the National Center for Advancing Translational Sciences of the National Institutes of Health, grant numbers UL1TR000448, KL2TR000450 and TL1TR000449; the National Cancer Institute of the National Institutes of Health, grant number 1KM1CA156708?01; an AHRQ R18 award, grant number R18HS0224181?01A1; and an unrestricted grant from MedAxiom Synergistic Healthcare Solutions Austin, TX.

Amin AP, et al. The evolving landscape of Impella use in the United States among patients undergoing percutaneous coronary intervention with mechanical circulatory support. Circulation. Nov. 17, 2019.

Washington University School of Medicine's 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.

Washington University School of Medicine

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.